MDMX (MDM4), a promising target for p53 reactivation therapy and beyond

Cold Spring Harbor Perspectives in Medicine

Volumn 6, Issue 7, 2016, Pages

  Marine, Jean Christophe ^a,b   Jochemsen, Aart G ^c  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; PROTEIN MDMX; PROTEIN P53; MDM2 PROTEIN, HUMAN; PROTEIN MDM2;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER THERAPY; HUMAN; NONHUMAN; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; RING FINGER MOTIF; RNA SPLICING; UPREGULATION; ZINC FINGER MOTIF; ANIMAL; ANTAGONISTS AND INHIBITORS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; NEOPLASM; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84977507230     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a026237     Document Type: Article

References (96)

1. Allende-Vega N, Sparks A, Lane DP, Saville MK. 2010. MdmX is a substrate for the deubiquitinating enzyme USP2a. Oncogene 29: 432-441.
2. Balint E, Bates S, Vousden KH. 1999. Mdm2 binds p73a without targeting degradation. Oncogene 18: 3923-3929.
3. Bardot B, Bouarich-Bourimi R, Leemput J, Lejour V, Hamon A, Plancke L, Jochemsen AG, Simeonova I, Fang M, Toledo F. 2015. Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity. Oncogene 34: 2943-2948.
4. Bartel F, Schulz J, Bohnke A, Blumke K, Kappler M, Bache M, Schmidt H, Wurl P, Taubert H, Hauptmann S. 2005. Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis. Int J Cancer 117: 469-475.
5. Bernal F, Wade M, Godes M, Davis TN, Whitehead DG, Kung AL, Wahl GM, Walensky LD. 2010. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell 18: 411-422.
6. Bezzi M, Teo SX, Muller J, Mok WC, Sahu SK, Vardy LA, Bonday ZQ, Guccione E. 2013. Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery. Genes Dev 27: 1903-1916.
7. Bista M, Smithson D, Pecak A, Salinas G, Pustelny K, Min J, Pirog A, Finch K, Zdzalik M, Waddell B, et al. 2012. On the mechanism of action of SJ-172550 in inhibiting the interaction of MDM4 and p53. PLoS ONE 7: e37518.
8. Bista M, Petrovich M, Fersht AR. 2013. MDMX contains an autoinhibitory sequence element. Proc Natl Acad Sci 110: 17814-17819.
9. Bo MD, Secchiero P, Degan M, Marconi D, Bomben R, Pozzato G, Gaidano G, Del PG, Forconi F, Zauli G, et al. 2010. MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3. Br J Haematol 150: 237-239.
10. Boesten LS, Zadelaar SM, De CS, Francoz S, van NA, Biessen EA, Hofmann F, Feil S, Feil R, Jochemsen AG, et al. 2006. Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53-mediated caspase-3-independent cell death. Cell Death Differ 13: 2089-2098.
11. Bottger V, Bottger A, Garcia-Echeverria C, Ramos YF, van der Eb AJ, Jochemsen AG, Lane DP. 1999. Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene 18: 189-199.
12. Boutz PL, Bhutkar A, Sharp PA. 2015. Detained introns are a novel, widespread class of post-transcriptionally spliced introns. Genes Dev 29: 63-80.
13. Carrillo AM, Bouska A, Arrate MP, Eischen CM. 2015. Mdmx promotes genomic instability independent of p53 and Mdm2. Oncogene 34: 846-856.
14. Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Car- rasco R, McDermott JL, Leach CA, Fulcinniti M, Kodrasov MP, et al. 2012. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 22: 345-358.
15. Chen L, Gilkes DM, Pan Y, Lane WS, Chen J. 2005a. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J 24: 3411-3422.
16. Chen L, Li C, Pan Y, Chen J. 2005b. Regulation of p53- MDMX interaction by casein kinase 1 a. Mol Cell Biol 25: 6509-6520.
17. Chen L, Borcherds W, Wu S, Becker A, Schonbrunn E, Daughdrill GW, Chen J. 2015. Autoinhibition of MDMX by intramolecular p53 mimicry. Proc Natl Acad Sci 112: 4624-4629.
18. Corbo C, Orru S, Salvatore F. 2013. SRp20: An overview of its role in human diseases. Biochem Biophys Res Commun 436: 1-5.
19. Daftuar L, Zhu Y, Jacq X, Prives C. 2013. Ribosomal proteins RPL37, RPS15 and RPS20 regulate the Mdm2-p53-MdmX network. PLoS ONE 8: e68667.
20. Danovi D, Meulmeester E, Pasini D, Migliorini D, Capra M, Frenk R, de GP, Francoz S, Gasparini P, Gobbi A, et al. 2004. Amplification of Mdmx (or Mdm4) directly con- tributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol 24: 5835-5843.
21. De Clercq S, Gembarska A, Denecker G, Maetens M, Naessens M, Haigh K, Haigh JJ, Marine JC. 2010. Widespread overexpression of epitope-tagged Mdm4 does not accel- erate tumor formation in vivo. Mol Cell Biol 30: 5394-5405.
22. de Lange J, Teunisse AF, Vries MV, Lodder K, Lam S, Luyten GP, Bernal F, Jager MJ, Jochemsen AG. 2012. High levels of Hdmx promote cell growth in a subset of uveal mela- nomas. Am J Cancer Res 2: 492-507.
23. Dewaele M, Tabaglio T, Willekens K, Bezzi M, Teo SX, Low DH, Koh CM, Rambow F, Fiers M, Rogiers A, et al. 2015. Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. J Clin Invest. doi: 10.1172/JCI82534.
24. Ding F, Bao C, Tian Y, Xiao H, Wang M, Xie X, Hu F, Mei J. 2015. USP22 promotes NSCLC tumorigenesis via MDMX up-regulation and subsequent p53 inhibition. Int J Mol Sci 16: 307-320.
25. Dobbelstein M, Wienzek S, Konig C, Roth J. 1999. Inactiva- tion of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene 18: 2101-2106.
26. Finch RA, Donoviel DB, Potter D, Shi M, Fan A, Freed DD, Wang CY, Zambrowicz BP, Ramirez-Solis R, Sands AT, et al. 2002. mdmx is a negative regulator of p53 activity in vivo. Cancer Res 62: 3221-3225.
27. Francoz S, Froment P, Bogaerts S, De CS, Maetens M, Dou- mont G, Bellefroid E, Marine JC. 2006. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci 103: 3232-3237.
28. Garcia D, Warr MR, Martins CP, Brown SL, Passegue E, Evan GI. 2011. Validation of MdmX as a therapeutic target for reactivating p53 in tumors. Genes Dev 25: 1746-1757.
29. Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, Zwolinska A, Haupt S, de LJ, Yip D, et al. 2012. MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med 18: 1239-1247.
30. Gilkes DM, Chen L, Chen J. 2006. MDMX regulation of p53 response to ribosomal stress. EMBO J 25: 5614-5625.
31. Gilkes DM, Pan Y, Coppola D, Yeatman T, Reuther GW, Chen J. 2008. Regulation of MDMX expression by mitogenic signaling. Mol Cell Biol 28: 1999-2010.
32. Grier JD, Yan W, Lozano G. 2002. Conditional allele of mdm2 which encodes a p53 inhibitor. Genesis 32: 145-147.
33. Grier JD, Xiong S, Elizondo-Fraire AC, Parant JM, Lozano G. 2006. Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol 26: 192-198.
34. Hair P, Cameron F, McKeage K. 2013. Mipomersen sodium: First global approval. Drugs 73: 487-493.
35. Han X, Garcia-Manero G, McDonnell TJ, Lozano G, Me- deiros LJ, Xiao L, Rosner G, Nguyen M, Fernandez M, Valentin-Vega YA, et al. 2007. HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target. Mod Pathol 20: 54-62.
36. Hsieh JK, Chan FS, O’Connor DJ, Mittnacht S, Zhong S, Lu X. 1999. RB regulates the stability and the apoptotic function of p53 via MDM2. Mol Cell 3: 181-193.
37. Hu J, Yang D, Zhang H, Liu W, Zhao Y, Lu H, Meng Q, Pang H, Chen X, Liu Y, et al. 2015. USP22 promotes tumor progression and induces epithelial-mesenchymal tran- sition in lung adenocarcinoma. Lung Cancer 88: 239-245.
38. Huang L, Yan Z, Liao X, Li Y, Yang J, Wang ZG, Zuo Y, Kawai H, Shadfan M, Ganapathy S, et al. 2011. The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proc Natl Acad Sci 108: 12001-12006.
39. Kawai H, Wiederschain D, Kitao H, Stuart J, Tsai KK, Yuan ZM. 2003a. DNA damage-induced MDMX degradation is mediated by MDM2. J Biol Chem 278: 45946-45953.
40. Kawai H, Wiederschain D, Yuan ZM. 2003b. Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Mol Cell Biol 23: 4939-4947.
41. Kornblihtt AR, Schor IE, Allo M, Dujardin G, Petrillo E, Munoz MJ. 2013. Alternative splicing: A pivotal step between eukaryotic transcription and translation. Nat Rev Mol Cell Biol 14: 153-165.
42. Kubo N, Okoshi R, Nakashima K, Shimozato O, Nakaga- wara A, Ozaki T. 2010. MDM2 promotes the proteasomal degradation of p73 through the interaction with Itch in HeLa cells. Biochem Biophys Res Commun 403: 405-411.
43. Landers JE, Haines DS, Strauss JF III, George DL. 1994. Enhanced translation: A novel mechanism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 9: 2745-2750.
44. Landers JE, Cassel SL, George DL. 1997. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res 57: 3562-3568.
45. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, et al. 2006. Inactivation of the p53 pathway in retinoblastoma. Nature 444: 61-66.
46. LeBron C, Chen L, Gilkes DM, Chen J. 2006. Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3. EMBO J 25: 1196-1206.
47. Lenos K, Jochemsen AG. 2011. Functions of MDMX in the modulation of the p53-response. J Biomed Biotechnol 2011: 876173.
48. Li M, Gu W. 2011. A critical role for noncoding 5S rRNA in regulating Mdmx stability. Mol Cell 43: 1023-1032.
49. Li X, Gilkes D, Li B, Cheng Q, Pernazza D, Lawrence H, Lawrence N, Chen J. 2012. Abnormal MDMX degradation in tumor cells due to ARF deficiency. Oncogene 31: 3721-3732.
50. Li L, Tan Y, Chen X, Xu Z, Yang S, Ren F, Guo H, Wang X, Chen Y, Li G, et al. 2014. MDM4 overexpressed in acute myeloid leukemia patients with complex karyotype and wild-type TP53. PLoS ONE 9: e113088.
51. Linke K, Mace PD, Smith CA, Vaux DL, Silke J, Day CL. 2008. Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ 15: 841-848.
52. Liu Y, He Y, Jin A, Tikunov AP, Zhou L, Tollini LA, Leslie P, Kim TH, Li LO, Coleman RA, et al. 2014. Ribosomal protein-Mdm2-p53 pathway coordinates nutrient stress with lipid metabolism by regulating MCD and promoting fatty acid oxidation. Proc Natl Acad Sci 111: E2414-E2422.
53. Lopez-Pajares V, Kim MM, Yuan ZM. 2008. Phosphorylation of MDMX mediated by Akt leads to stabilization and induces 14-3-3 binding. J Biol Chem 283: 13707-13713.
54. Mancini F, Gentiletti F, D’Angelo M, Giglio S, Nanni S, D’Angelo C, Farsetti A, Citro G, Sacchi A, Pontecorvi A, et al. 2004. MDM4 (MDMX) overexpression enhances stabilization of stress-induced p53 and promotes apoptosis. J Biol Chem 279: 8169-8180.
55. Mancini F, Di CG, Pellegrino M, Rinaldo C, Prodosmo A, Giglio S, D’Agnano I, Florenzano F, Felicioni L, Buttitta F, et al. 2009. MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. EMBO J 28: 1926-1939.
56. Mancini F, Pieroni L, Monteleone V, Lucà R, Fici L, Luca E, Urbani A, Xiong S, Soddu S, Masetti R, et al. 2015. MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response. Oncogene. doi: 10.1038/onc.2015.76.
57. McCoy MA, Gesell JJ, Senior MM, Wyss DF. 2003. Flexible lid to the p53-binding domain of human Mdm2: Implications for p53 regulation. Proc Natl Acad Sci 100: 1645-1648.
58. McEvoy J, Ulyanov A, Brennan R, Wu G, Pounds S, Zhang J, Dyer MA. 2012. Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma. PLoS ONE 7: e42739.
59. Mendrysa SM, McElwee MK, Michalowski J, O’Leary KA, Young KM, Perry ME. 2003. mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol 23: 462-472.
60. Meulmeester E, Frenk R, Stad R, de GP, Marine JC, Vousden KH, Jochemsen AG. 2003. Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol Cell Biol 23: 4929-4938.
61. Meulmeester E, Maurice MM, Boutell C, Teunisse AF, Ovaa H, Abraham TE, Dirks RW, Jochemsen AG. 2005. Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol Cell 18: 565-576.
62. Migliorini D, Lazzerini DE, Danovi D, Jochemsen A, Capillo M, Gobbi A, Helin K, Pelicci PG, Marine JC. 2002. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol Cell Biol 22: 5527-5538.
63. Monteleone G, Neurath MF, Ardizzone S, Di SA, Fantini MC, Castiglione F, Scribano ML, Armuzzi A, Caprioli F, Sturniolo GC, et al. 2015. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease. N Engl J Med 372: 1104-1113.
64. Okamoto K, Kashima K, Pereg Y, Ishida M, Yamazaki S, Nota A, Teunisse A, Migliorini D, Kitabayashi I, Marine JC, et al. 2005. DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Mol Cell Biol 25: 9608-9620.
65. Ongkeko WM, Wang XQ, Siu WY, Lau AW, Yamashita K, Harris AL, Cox LS, Poon RY. 1999. MDM2 and MDMX bind and stabilize the p53-related protein p73. Curr Biol 9: 829-832.
66. Pant V, Xiong S, Iwakuma T, Quintas-Cardama A, Lozano G. 2011. Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proc Natl Acad Sci 108: 11995-12000.
67. Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG, Lozano G. 2001. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet 29: 92-95.
68. Pereg Y, Shkedy D, de GP, Meulmeester E, Edelson-Averbukh M, Salek M, Biton S, Teunisse AF, Lehmann WD, et al. 2005. Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage. Proc Natl Acad Sci 102: 5056-5061.
69. Pereg Y, Lam S, Teunisse A, Biton S, Meulmeester E, Mittel- man L, Buscemi G, Okamoto K, Taya Y, Shiloh Y, et al. 2006. Differential roles of ATM- and Chk2-mediated phosphorylations of Hdmx in response to DNA damage. Mol Cell Biol 26: 6819-6831.
70. Perez-Ortin JE, Alepuz P, Chavez S, Choder M. 2013. Eukaryotic mRNA decay: Methodologies, pathways, and links to other stages of gene expression. J Mol Biol 425: 3750-3775.
71. Popp MW, Maquat LE. 2013. Organizing principles of mammalian nonsense-mediated mRNA decay. Annu Rev Genet 47: 139-165.
72. Poyurovsky MV, Priest C, Kentsis A, Borden KL, Pan ZQ, Pavletich N, Prives C. 2007. The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. EMBO J 26: 90-101.
73. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, et al. 2010. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo- controlled trial. Lancet 375: 998-1006.
74. Rallapalli R, Strachan G, Cho B, Mercer WE, Hall DJ. 1999. A novel MDMX transcript expressed in a variety of transformed cell lines encodes a truncated protein with potent p53 repressive activity. J Biol Chem 274: 8299-8308.
75. Rallapalli R, Strachan G, Tuan RS, Hall DJ. 2003. Identification of a domain within MDMX-S that is responsible for its high affinity interaction with p53 and high-level expression in mammalian cells. J Cell Biochem 89: 563-575.
76. Reed D, Shen Y, Shelat AA, Arnold LA, Ferreira AM, Zhu F, Mills N, Smithson DC, Regni CA, Bashford D, et al. 2010. Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem 285: 10786-10796.
77. Riemenschneider MJ, Buschges R, Wolter M, Reifenberger J, Bostrom J, Kraus JA, Schlegel U, Reifenberger G. 1999. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant glio- mas without TP53 mutation or MDM2 amplification. Cancer Res 59: 6091-6096.
78. Ringshausen I, O’Shea CC, Finch AJ, Swigart LB, Evan GI. 2006. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 10: 501-514.
79. Sabbatini P, McCormick F. 2002. MDMX inhibits the p300/ CBP-mediated acetylation of p53. DNACell Biol 21: 519-525.
80. Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, Bazuine M, van Ham RC, van der Houven van Oordt W, Hateboer G, et al. 1996 MDMX: A novel p53-binding protein with some functional properties of MDM2. EMBO J 15: 5349-5357.
81. Steinman HA, Jones SN. 2002. Generation of an Mdm2 conditional allele in mice. Genesis 32: 142-144.
82. Tang B, Tang F, Li B, Yuan S, Xu Q, Tomlinson S, Jin J, Hu W, He S. 2015. High USP22 expression indicates poor prog- nosis in hepatocellular carcinoma. Oncotarget 6: 12654-12667.
83. Toledo F, Krummel KA, Lee CJ, Liu CW, Rodewald LW, Tang M, Wahl GM. 2006. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and pro- vides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 9: 273-285.
84. Uchida C, Miwa S, Isobe T, Kitagawa K, Hattori T, Oda T, Yasuda H, Kitagawa M. 2006. Effects of MdmX on Mdm2-mediated downregulation of pRB. FEBS Lett 580: 1753-1758.
85. Valentin-Vega YA, Box N, Terzian T, Lozano G. 2009. Mdm4 loss in the intestinal epithelium leads to compartmentalized cell death but no tissue abnormalities. Differentiation 77: 442-449.
86. Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature 408: 307-310.
87. Wang X, Arooz T, Siu WY, Chiu CH, Lau A, Yamashita K, Poon RY. 2001. MDM2 and MDMX can interact differently with ARF and members of the p53 family. FEBS Lett 490: 202-208.
88. Wang CL, Wang JY, Liu ZY, Ma XM, Wang XW, Jin H, Zhang XP, Fu D, Hou LJ, Lu YC. 2014. Ubiquitin-specific protease 2a stabilizes MDM4 and facilitates the p53- mediated intrinsic apoptotic pathway in glioblastoma. Carcinogenesis 35: 1500-1509.
89. Worrall EG, Wawrzynow B, Worrall L, Walkinshaw M, Ball KL, Hupp TR. 2009. Regulation of the E3 ubiquitin ligase activity of MDM2 by an N-terminal pseudo-substrate motif. J Chem Biol 2: 113-129.
90. Worrall EG, Worrall L, Blackburn E, Walkinshaw M, Hupp TR. 2010. The effects of phosphomimetic lid mutation on the thermostability of the N-terminal domain of MDM2. J Mol Biol 398: 414-428.
91. Wu H, Leng RP. 2015. MDM2 mediates p73 ubiquitination: A new molecular mechanism for suppression of p73 function. Oncotarget 28: 21479-21492.
92. Wu S, Chen L, Becker A, Schonbrunn E, Chen J. 2012. Casein kinase 1a regulates an MDMX intramolecular interaction to stimulate p53 binding. Mol Cell Biol 32: 4821-4832.
93. Xiong S, Van Pelt CS, Elizondo-Fraire AC, Liu G, Lozano G. 2006. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci 103: 3226-3231.
94. Zdzalik M, Pustelny K, Kedracka-Krok S, Huben K, Pecak A, Wladyka B, Jankowski S, Dubin A, Potempa J, Dubin G. 2010. Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73. Cell Cycle 9: 4584-4591.
95. Zeng X, Chen L, Jost CA, Maya R, Keller D, Wang X, Kaelin WG Jr, Oren M, Chen J, Lu H. 1999. MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol 19: 3257-3266.
96. Zhang H, Hu L, Qiu W, Deng T, Zhang Y, Bergholz J, Xiao ZX. 2015. MDMX exerts its oncogenic activity via suppression of retinoblastoma protein. Oncogene doi: 10.1038/onc.2015.11.